GTHP Stock Overview
A medical technology company, develops medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Guided Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$0.25 |
| 52 Week Low | US$0.064 |
| Beta | 0.50 |
| 11 Month Change | 15.19% |
| 3 Month Change | 54.17% |
| 1 Year Change | 31.22% |
| 33 Year Change | -71.09% |
| 5 Year Change | 2.92% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| GTHP | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.8% | 1.7% | 0.3% |
| 1Y | 31.2% | 21.4% | 31.1% |
Return vs Industry: GTHP exceeded the US Medical Equipment industry which returned 21.4% over the past year.
Return vs Market: GTHP matched the US Market which returned 31.1% over the past year.
Price Volatility
| GTHP volatility | |
|---|---|
| GTHP Average Weekly Movement | 36.4% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GTHP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GTHP's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 4 | Mark Faupel | www.guidedinc.com |
Guided Therapeutics, Inc., a medical technology company, develops medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008.
Guided Therapeutics, Inc. Fundamentals Summary
| GTHP fundamental statistics | |
|---|---|
| Market cap | US$10.91m |
| Earnings (TTM) | -US$2.36m |
| Revenue (TTM) | US$38.00k |
297.0x
P/S Ratio-4.8x
P/E RatioIs GTHP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTHP income statement (TTM) | |
|---|---|
| Revenue | US$38.00k |
| Cost of Revenue | US$18.00k |
| Gross Profit | US$20.00k |
| Other Expenses | US$2.38m |
| Earnings | -US$2.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 52.63% |
| Net Profit Margin | -6,210.53% |
| Debt/Equity Ratio | -44.0% |
How did GTHP perform over the long term?
See historical performance and comparison